SCHEMBL8273311

SCHEMBL8273311

Nc1cc(F)ccc1N1CCC(CNC(=O)[C@H](O)[C@@H](O)C(=O)N2CC[C@H](N)C2)CC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ADAM17 P78536 6/20 0.41
▸ HTT P42858 2/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ RPS6KB1 P23443 2/20 0.35
▸ CACNA1B Q00975 2/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SCN5A Q14524 1/20 0.34
▸ SCN9A Q15858 1/20 0.34
▸ GHSR Q92847 1/20 0.33
▸ F10 P00742 1/20 0.33
▸ CHRM4 P08173 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8273578 0.91 ADAM17 (0.39) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8222728 0.89 ADAM17 (0.49) ADAM17RPS6KB1SCN5ASCN9ACHRM4
SCHEMBL8273310 0.89 GAA (0.44) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8273591 0.89 ADAM17 (0.43) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8273592 0.88 HTT (0.46) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8273582 0.88 ADAM17 (0.47) ADAM17GAAKDM4EHDAC3HDAC1
SCHEMBL8273579 0.86 CTSS (0.41) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8273588 0.86 ADAM17 (0.40) ADAM17HTTALDH1A1GAAKDM4E
SCHEMBL8274407 0.85 ADAM17 (0.43) ADAM17HTTALDH1A1GAAL3MBTL1
SCHEMBL8276118 0.85 ADAM17 (0.43) ADAM17HTTALDH1A1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005121130-A2 CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2005-12-22 — — WO disclosed
Send feedback